Sun Pharma and AstraZeneca enter into distribution agreement for ticagrelor in India

Mumbai & Bangalore, India: June 2, 2015 - Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) and AstraZeneca Pharma India Limited (AZPIL) (BSE : 506820, NSE : ASTRAZEN, AZPIL) today announced that AZPIL and Sun Pharma have entered into a distribution services agreement in India for AstraZeneca's brand "Axcer®", a new brand of ticagrelor, a drug used for the treatment of acute coronary syndrome (ACS) . AZPIL already has a brand under the trademark "Brilinta®", for ticagrelor molecule, launched and marketed by AZPIL in India since 2012.

Abhay Gandhi, CEO - India Business, Sun Pharma said, *"We are happy to collaborate with AstraZeneca to provide customers access to this latest generation treatment option for ACS. Such collaborations are also a part of our stated policy of becoming the partner of choice for promotion and distribution of innovative pharmaceutical products in the country."*

Sanjay Murdeshwar, Managing Director, AstraZeneca Pharma India Limited said, *"We are pleased to collaborate with Sun Pharmaceuticals to bring this innovative treatment solution to a larger number of ACS patients in India. Ticagrelor works by preventing the formation of new blood clots and maintains blood flow in the body, helping reduce a patient's risk of another heart attack or cardiovascular-related death."*

Sun Pharma will be promoting and distributing "Axcer®" brand in India. This collaboration enables AstraZeneca to expand usage of this molecule through wider reach to physicians and thereby benefiting a greater number of ACS patients. It strengthens Sun Pharma's cardiology portfolio with the addition of a new patented therapy.

NOTES TO EDITORS

About Ticagrelor

Ticagrelor is a direct-acting, selective and reversibly binding P2Y12 receptor antagonist in a chemical class called cyclo-pentyl-triazolo-pyrimidines (CPTPs). Ticagrelor works by inhibiting platelet activation.Ticagrelor (90mg) is indicated to reduce the rate of thrombotic CV events in patients with ACS (unstable angina [UA], non–ST-elevation myocardial infarction [NSTEMI], or ST-elevation myocardial infarction [STEMI]). Ticagrelor has been shown to reduce the rate of a combined end point of CV death, MI, or stroke compared to clopidogrel. The difference between treatments was driven by CV death and MI with no difference in stroke. In patients treated with percutaneous coronary intervention, it also reduces the rate of stent thrombosis.

About Sun Pharmaceutical Industries Ltd. (CIN - L24230GJ1993PLC019050):

Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma's global presence is supported by 45 manufacturing facilities spread across 5 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. The consolidated revenues for 12 months ending March 2015 are approximately US$ 4.5 billion, of which US contributes US$ 2.2 billion. In India, the company enjoys leadership across 12 different classes of doctors with 31 brands featuring amongst top 300 pharmaceutical brands in India. Its footprint across emerging markets

covers over 50 countries and 6 markets in Western Europe. Its Global Consumer Healthcare business is ranked amongst Top 10 across 4 global markets. Its API business footprint is strengthened through 11 world class API manufacturing facilities across the globe. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 1800 scientists and R&D investments of over 7% of annual revenues. For further information please visit www.sunpharma.com

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit www.astrazeneca.com

CONTACTS

Sun Pharma:

Nimish Desai	
Tel	+91 22 4324 4324, Xtn 2778
Tel Direct	+91 22 4324 2778
Mobile	+91-98203 30182
E mail	nimish.desai@sunpharma.com

Frederick Castro	
Tel	+91 22 4324 4324, Xtn 2777
Tel Direct	+91 22 4324 2777
Mobile	+91 99206 65176
E mail	frederick.castro@sunpharma.com

AstraZeneca Pharma India:

Varsha Das	
Tel	+91 80.67748497
Mobile	+91. 9741752900
E mail	Varsha.das@edelman.com